| Bioactivity |
Frentizole, an FDA-approved immunosuppressant, is a Aβ-ABAD (binding alcohol dehydrogenase) interaction inhibitor with an IC50 value of 200 μM. Frentizole is used in studies of diseases related to rheumatoid arthritis and systemic lupus erythematosus[1][2][3]. |
| Invitro |
Frentizole (500 ng/mL, 48 hours) is effective in inhibiting thymidine incorporation into DNA when adds to lymphocyte cultures alongside mitogens, and significantly inhibits the response to concanavalin A by 58% in a dose-dependent manner in lymphocytes extracted from mice peritoneal cavity[1]. Frentizole (62.5 ng/mL) can effectively inhibit uridine incorporation and the inhibition of uridine incorporation is independent of the phytochemical used[1]. |
| In Vivo |
Frentizole (8.2 or 79.9 mg/kg/day for young mice in animal feedings, 52 weeks) can extend the life span of NZB/NZW mice[2]. Animal Model: |
| Name |
Frentizole |
| CAS |
26130-02-9 |
| Formula |
C15H13N3O2S |
| Molar Mass |
299.35 |
| Appearance |
Solid |
| Transport |
Room temperature in continental US; may vary elsewhere. |
| Storage |
| Powder |
-20°C |
3 years |
|
4°C |
2 years |
| In solvent |
-80°C |
6 months |
|
-20°C |
1 month |
|
| Reference |
[1]. Meisel AD, et al. Effect of frentizole on mitogen-induced blastogenesis in human lymphocytes. J Immunopharmacol. 1979;1(4):483-95. [2]. Walker SE, et al. Prolonged lifespans in female NZB/NZW mice treated with the experimental immunoregulatory drug frentizole. Arthritis Rheum. 1982 Nov;25(11):1291-7. [3]. Yuli Xie, et al. Identification of small-molecule inhibitors of the Abeta-ABAD interaction. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4657-60. |
